{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:08:44Z","timestamp":1788541724678,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.phrs.2020.105256","type":"journal-article","created":{"date-parts":[[2020,10,18]],"date-time":"2020-10-18T09:50:21Z","timestamp":1603014621000},"page":"105256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"163","author":[{"given":"Jing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong-Hong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-Xin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-Ming","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2020.105256_bib0005","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.phrs.2020.105256_bib0010","first-page":"S11","article-title":"KDOQI clinical practice guidelines and clinical practice recommendations for Anemia in chronic kidney disease","volume":"47","author":"National Kidney Foundation","year":"2006","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.phrs.2020.105256_bib0015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2215\/CJN.00630208","article-title":"Health-related quality of life and hemoglobin levels in chronic kidney disease patients","volume":"4","author":"Finkelstein","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"2018","key":"10.1016\/j.phrs.2020.105256_bib0020","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.ajkd.2017.09.026","article-title":"Update on Anemia in ESRD and earlier stages of CKD: core curriculum","volume":"71","author":"Fishbane","year":"2018","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.phrs.2020.105256_bib0025","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMra041809","article-title":"Anemia of chronic disease","volume":"352","author":"Weiss","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.105256_bib0030","doi-asserted-by":"crossref","DOI":"10.1038\/ki.2010.188","article-title":"Anemia management in chronic kidney disease","author":"Fishbane","year":"2010","journal-title":"Kidney Int. Suppl. (2011)"},{"key":"10.1016\/j.phrs.2020.105256_bib0035","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nrneph.2015.82","article-title":"Anaemia in kidney disease: harnessing hypoxia responses for therapy","volume":"11","author":"Koury","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.phrs.2020.105256_bib0040","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.105256_bib0045","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.105256_bib0050","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.ajkd.2009.12.030","article-title":"Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD","volume":"55","author":"Babitt","year":"2010","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.phrs.2020.105256_bib0055","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.ajkd.2016.05.031","article-title":"Spectrum and burden of erythropoiesis-stimulating agent hyporesponsiveness among contemporary hemodialysis patients","volume":"68","author":"Luo","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.phrs.2020.105256_bib0060","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/ndt\/gfl716","article-title":"Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients","volume":"22","author":"Rossert","year":"2007","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.phrs.2020.105256_bib0065","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2020.105256_bib0070","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1681\/ASN.2019020213","article-title":"Iron deficiency in chronic kidney disease: updates on pathophysiology, diagnosis, and treatment","volume":"31","author":"Batchelor","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2020.105256_bib0075","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2215\/CJN.00080116","article-title":"Iron therapy challenges for the treatment of nondialysis CKD patients","volume":"11","author":"Locatelli","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2020.105256_bib0080","article-title":"Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions","volume":"10","author":"Macdougall","year":"2017","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.phrs.2020.105256_bib0085","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41581-019-0207-7","article-title":"A new approach to treating renal anaemia","volume":"15","author":"Maxwell","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.phrs.2020.105256_bib0090","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41581-019-0182-z","article-title":"Mechanisms of hypoxia signalling: new implications for nephrology","volume":"15","author":"Schodel","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.phrs.2020.105256_bib0095","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1172\/JCI38499","article-title":"HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice, J. Clin","volume":"119","author":"Mastrogiannaki","year":"2009","journal-title":"Invest."},{"key":"10.1016\/j.phrs.2020.105256_bib0100","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cmet.2008.12.012","article-title":"Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency","volume":"9","author":"Shah","year":"2009","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2020.105256_bib0105","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1053\/j.gastro.2011.03.007","article-title":"Hypoxia-inducible factor-2alpha mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice","volume":"140","author":"Taylor","year":"2011","journal-title":"Gastroenterology."},{"key":"10.1016\/j.phrs.2020.105256_bib0110","doi-asserted-by":"crossref","first-page":"20055","DOI":"10.1074\/jbc.272.32.20055","article-title":"Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1","volume":"272","author":"Rolfs","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2020.105256_bib0115","doi-asserted-by":"crossref","first-page":"24142","DOI":"10.1074\/jbc.274.34.24142","article-title":"Transferrin receptor induction by hypoxia. HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation","volume":"274","author":"Tacchini","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2020.105256_bib0120","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1053\/j.ajkd.2016.12.011","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for Anemia in patients with CKD","volume":"69","author":"Gupta","year":"2017","journal-title":"Am. J. Kidney Dis."},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2020.105256_bib0125","first-page":"S110","article-title":"HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism","volume":"21","author":"Haase","year":"2017","journal-title":"Hemodial. Int."},{"key":"10.1016\/j.phrs.2020.105256_bib0130","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1053\/j.ackd.2019.04.004","article-title":"Hypoxia-inducible factor activators in renal Anemia: current clinical experience","volume":"26","author":"Sanghani","year":"2019","journal-title":"Adv. Chronic Kidney Dis."},{"key":"10.1016\/j.phrs.2020.105256_bib0135","doi-asserted-by":"crossref","first-page":"720","DOI":"10.21037\/atm.2019.12.18","article-title":"Effectiveness of hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat on renal anemia in non-dialysis-dependent chronic kidney disease: a systematic review and meta-analysis","volume":"7","author":"Jia","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.phrs.2020.105256_bib0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104747","article-title":"Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: a systematic review and meta-analysis","volume":"155","author":"Liu","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2020.105256_bib0145","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.2147\/DDDT.S175887","article-title":"The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease","volume":"12","author":"Zhong","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.phrs.2020.105256_bib0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105020","article-title":"Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: a network meta-analysis","volume":"159","author":"Zheng","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2020.105256_bib0155","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s11255-018-1940-8","article-title":"Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis","volume":"50","author":"Xie","year":"2018","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.phrs.2020.105256_bib0160","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ."},{"key":"10.1016\/j.phrs.2020.105256_bib0165","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ."},{"key":"10.1016\/j.phrs.2020.105256_bib0170","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.phrs.2020.105256_bib0175","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.phrs.2020.105256_bib0180","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.0","author":"Higgins","year":"2019"},{"key":"10.1016\/j.phrs.2020.105256_bib0185","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for Anemia in patients with kidney disease not receiving Dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.105256_bib0190","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1007\/s12325-019-00943-4","article-title":"Roxadustat treatment of chronic kidney disease-associated Anemia in japanese patients not on Dialysis: a phase 2, randomized, double-blind, placebo-controlled trial","volume":"36","author":"Akizawa","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.phrs.2020.105256_bib0195","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/ndt\/gfx011","article-title":"Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China","volume":"32","author":"Chen","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.phrs.2020.105256_bib0200","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","article-title":"Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients","volume":"30","author":"Besarab","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.phrs.2020.105256_bib0205","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1053\/j.ajkd.2015.11.021","article-title":"A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for Anemia in CKD: a 28-Day, phase 2A randomized trial","volume":"67","author":"Brigandi","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.phrs.2020.105256_bib0210","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1681\/ASN.2014111139","article-title":"Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of Anemia","volume":"27","author":"Holdstock","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2020.105256_bib0215","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ckj\/sfy013","article-title":"Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease","volume":"12","author":"Holdstock","year":"2019","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.phrs.2020.105256_bib0220","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000464476","article-title":"Clinical trial of Vadadustat in patients with Anemia Secondary to stage 3 or 4 chronic kidney disease","volume":"45","author":"Martin","year":"2017","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.phrs.2020.105256_bib0225","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.kint.2016.07.019","article-title":"Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease","volume":"90","author":"Pergola","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.phrs.2020.105256_bib0230","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000496929","article-title":"Randomized trial of enarodustat in patients with chronic kidney disease followed by long-term trial","volume":"49","author":"Akizawa","year":"2019","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.phrs.2020.105256_bib0235","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2215\/CJN.02510218","article-title":"Effects of Molidustat in the treatment of Anemia in CKD","volume":"14","author":"Macdougall","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2020.105256_bib0240","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000500232","article-title":"Outcomes of desidustat treatment in people with Anemia and chronic kidney disease: a phase 2 study","volume":"49","author":"Parmar","year":"2019","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.phrs.2020.105256_bib0245","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2215\/CJN.04280609","article-title":"Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease?","volume":"5","author":"Stancu","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2020.105256_bib0250","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nrneph.2010.139","article-title":"Iron supplementation to treat anemia in patients with chronic kidney disease","volume":"6","author":"Besarab","year":"2010","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.phrs.2020.105256_bib0255","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1097\/01.ASN.0000034200.82278.DC","article-title":"Iron status and hemoglobin level in chronic renal insufficiency","volume":"13","author":"Hsu","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2020.105256_bib0260","doi-asserted-by":"crossref","unstructured":"Chapter 2: Use of iron to treat anemia in CKD, Kidney Int Suppl (2011). 2 (2012) 292-298. https:\/\/doi.org\/10.1038\/kisup.2012.34.","DOI":"10.1038\/kisup.2012.34"},{"key":"10.1016\/j.phrs.2020.105256_bib0265","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1182\/blood-2008-02-139915","article-title":"Immunoassay for human serum hepcidin","volume":"112","author":"Ganz","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.phrs.2020.105256_bib0270","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2215\/CJN.05931108","article-title":"Hepcidin--a potential novel biomarker for iron status in chronic kidney disease","volume":"4","author":"Zaritsky","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2020.105256_bib0275","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1681\/ASN.2006070802","article-title":"Molecular control of iron transport","volume":"18","author":"Ganz","year":"2007","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820315644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820315644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:20:48Z","timestamp":1760912448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661820315644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":55,"alternative-id":["S1043661820315644"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105256","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105256","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105256"}}